HIV/AIDS Topics HIV-Related Conditions Bone Loss/Osteoporosis
HIV Treatment Interruption Associated with Reduced Bone Loss in SMART Trial
- Details
- Category: Bone Loss/Osteoporosis
- Published on Tuesday, 15 January 2013 00:00
- Written by Liz Highleyman
People who stopped antiretroviral therapy (ART) in the SMART trial had less bone loss and lower levels of bone metabolism biomarkers than people who remained on continuous treatment, according to a report in the January 8, 2013, advance edition of Journal of Bone Mineral Research.
Study Finds Increased Fractures in First 2 Years after Starting Antiretroviral Treatment
- Details
- Category: HIV Treatment
- Published on Friday, 14 December 2012 00:00
- Written by Paul Dalton
HIV positive individuals appear to have significantly increased risk of bone fractures during the first 2 years after beginning antiretroviral therapy (ART), but the risk returned to baseline levels thereafter, according to a study published in the November 2012 issue of the journal AIDS.
HIV/HCV Coinfected People Have Higher Risk of Hip Fractures
- Details
- Category: Bone Loss/Osteoporosis
- Published on Friday, 22 June 2012 00:00
- Written by Liz Highleyman
HIV positive people who also have hepatitis C virus (HCV) are more prone to hip fractures than people with HIV alone, HCV alone, or neither virus, according to research published in the May 22, 2012, advance online edition of Hepatology.
ICAAC 2012: Simplified Abacavir/Atazanavir Combo Keeps HIV Suppressed, May Help Bones
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 10 October 2012 00:00
- Written by Liz Highleyman
Substituting abacavir/lamivudine (the drugs in Epzicom) for tenofovir/emtricitabine (the drugs in Truvada) and dropping the ritonavir (Norvir) booster with atazanavir (Reyataz) maintains undetectable HIV viral load and improves biomarkers of bone loss, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) last month in San Francisco. 
Young Men on Antiretroviral Therapy at Risk for Bone Loss
- Details
- Category: Bone Loss/Osteoporosis
- Published on Wednesday, 20 June 2012 00:00
- Written by Liz Highleyman
May 9, 2012, advance online edition of Clinical Infectious Diseases.
ICAAC 2012: Bone Loss Is Common in French HIV Cohort, Linked to Older Age and Lower Weight
- Details
- Category: HIV-Related Conditions
- Published on Friday, 28 September 2012 00:00
- Written by Liz Highleyman
As many as half of people with HIV may have some degree of bone loss -- and up to 20% may experience fractures -- but no other significant risk factors could be determined other than older age and low body mass index, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this month in San Francisco.
Bisphosphonate Drugs Linked to Atypical Femur Fractures, but Absolute Risk is Small
- Details
- Category: Bone Loss/Osteoporosis
- Published on Wednesday, 23 May 2012 00:00
- Written by Press Release
Use of bisphosphonates, a class of drugs used to manage bone loss and prevent fractures, actually appears to increase the likelihood of an unusual type of femur (thigh bone) fracture, according to a retrospective analysis described in the advance online edition of Archives of Internal Medicine. Researchers emphasized, however, that the absolute risk of atypical femur breaks remains very low.
AIDS 2012: HIV+ Men Prone to Bone Fractures at Earlier Age
- Details
- Category: Bone Loss/Osteoporosis
- Published on Tuesday, 21 August 2012 00:00
- Written by Liz Highleyman
HIV positive men in the long-running MACS cohort appeared to sustain osteoporosis-related bone fractures at an earlier age than HIV negative men, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC. A related study found several factors that predict greater risk of fractures, including use of protease inhibitors and proton pump inhibitors.
Zoledronate Protects HIV Positive Men against Bone Loss for at Least 5 Years
- Details
- Category: Bone Loss/Osteoporosis
- Published on Tuesday, 10 April 2012 00:00
- Written by Gregory Fowler
The effects of 2 annual doses of zoledronate persist for at least 5 years in HIV positive men on antiretroviral therapy (ART), according to a New Zealand study published in the March 14, 2012, advance online edition of the Journal of Clinical Endocrinology & Metabolism.
More Articles...
- CROI: Switching to Tenofovir Increases Bone Turnover, Raltegravir Can Improve Bone Density
- Conflicting Data on Bone Fracture Link to HIV Meds
- Vitamin D May Improve Bone Health in Young HIV+ People Taking Tenofovir
- HIV+ People on ART Have Stable Bone Density after Short-term Loss
- FDA Considers Limits on Osteoporosis Drugs Due to Fracture Risk
- Age-Related Fractures Due to Reduced Bone Quality as well as Quantity
- IAS 2011: Doubt Remains if HIV Therapy Increases the Risk of Fragility Fractures
- IAS 2011: Coronary Artery Calcification Linked to Bone Loss
- Low CD4 Count Linked to Bone Fractures
- CROI: HIV/HCV Coinfected People Have Higher Risk of Bone Loss
- Prevention Task Force Recommends Wider Bone Screening for Older Women
- People with HIV Have Increased Bone Fracture Risk
- Is Bone Loss Related to Immune Reconstitution in People on ART?
- FDA Warns of Unusual Femur Fractures in People Taking Bisphosphonates for Osteoporosis
- Bone Loss and Low Vitamin D Levels Are Common among People with HIV
- CROI: Low Vitamin D Levels Less Likely with Rilpivirine than Efavirenz
- Zoledronate Improves Bone Loss in People with HIV
Web Design and Development by